There are at least ten distinct classes of medications approved to treat T2D: sulfonylureas, meglitinides, amylin mimetics, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, glucagon-like peptide-1 analogs (GLP-1a), dipeptidyl peptidase-4 inhibitors (DPPi), sodium-glucose co-transporter (SGLT)-2 inhibitors (SGLT2i), and insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.